MetaVia's obesity drug DA-1726 shows promise, to be presented at EASL Congress 2026 in Spain.

MetaVia Inc. announced that its novel obesity drug candidate DA-1726, a dual GLP-1 and glucagon receptor agonist, will be featured in a late-breaking poster at the EASL Congress 2026 in Barcelona. DA-1726 aims to reduce weight by decreasing appetite and increasing energy use, showing superior results in pre-clinical studies compared to existing treatments. The drug is currently in a Phase 1 trial to optimize dosing, with results expected in Q4 2026. This highlights MetaVia's progress in developing innovative treatments for cardiometabolic diseases.